In conclusion, our current study demonstrated that sorafenib was able to reverse the TGF-β1-enhanced ovarian cancer cell EMT and, therefore, suppressed ovarian cancer SKOV-3 cell proliferation and mobility as well as enhanced the radiosensitivity of these cells in vitro. The gene discussed is TGFB1; the disease is ovarian carcinoma.